Speriolin Is a Novel Spermatogenic Cell-specific Centrosomal Protein Associated with the Seventh WD Motif of Cdc20

Masuo Goto‡§§ and Edward M. Eddy‡‡

From the §Gamete Biology Section, Laboratory of Reproductive and Developmental Toxicology, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709 and the ¶Department of Cell and Developmental Biology, University of North Carolina, Chapel Hill, North Carolina 27599

The fundamental mechanisms of mitosis are conserved throughout evolution in eukaryotes, including ubiquitin-mediated proteolysis of cell cycle regulators by the anaphase-promoting complex/cyclosome. The spindle checkpoint protein Cdc20 activates the anaphase-promoting complex/cyclosome in a substrate-specific manner. It is present in the cytoplasm and concentrated in the centrosomes throughout the cell cycle, accumulates at the kinetochores in metaphase, and is no longer detected following anaphase. However, it is unknown whether Cdc20 has the same activities and distribution during meiosis in male germ cells. We found that in mice, Cdc20 accumulates in the cytoplasm of pachytene spermatocytes during meiosis I, is distributed throughout spermatocytes undergoing meiotic division, and is present in the cytoplasm of postmeiotic spermatids. Several proteins bind to and regulate the function of Cdc20 during meiosis. We identified speriolin and determined that it is a novel spermatogenic cell-specific Cdc20-binding protein, is present in the cytoplasm, and is concentrated at the centrosomes of spermatocytes and spermatids and that a leucine zipper domain is required to target speriolin to the centrosome. The seven tandem WD motifs of Cdc20 probably fold into a seven-blade β-propeller structure, and we determined that they are required for speriolin binding and for localization of Cdc20 to the centrosomes and nucleus, suggesting that speriolin might regulate or stabilize the folding of Cdc20 during meiosis in spermatogenic cells.

Received for publication, March 22, 2004, and in revised form, July 21, 2004
Published, JBC Papers in Press, July 26, 2004, DOI 10.1074/jbc.M403190200

The mitotic phase of the cell cycle progresses by the periodic activation and inactivation of regulatory proteins by phosphorylation and dephosphorylation (1) and by their selective destruction via the ubiquitin-proteasome pathway (2). The multienzyme anaphase-promoting complex/cyclosome (APC) is the core regulatory component in this pathway (3), and a substrate-specific recruiting subunit, either Cdc20 or Cdh1, is essential for APC activation. Cdc20 is activated early in mitosis and signals the ubiquitin-mediated destruction of cyclin A, securin, and other proteins and is then degraded, whereas Cdh1 is activated during anaphase and telophase to trigger the destruction of additional substrates (2).

The location of Cdc20 in somatic cells changes during the cell cycle. In interphase, it is concentrated in the centrosomes and distributed diffusely at low levels throughout the nucleus and cytoplasm. During mitosis, Cdc20 accumulates in the nucleus in prophase, is concentrated at the kinetochores in metaphase until all chromosomes are aligned at the metaphase plate, and is no longer detected after late anaphase (4, 5). The N-terminal 167 amino acids are required for Cdc20 to associate with centrosomes (6), and this region also contains the binding domains for the spindle checkpoint protein Mad2 and the early mitotic regulator Emi1 (7–9). Mad2 competes with APC binding to the N-terminal region of Cdc20 until all kinetochores achieve bipolar attachment to the mitotic spindle, whereas Emi1 prevents Cdc20 interaction with substrates without inhibiting binding to the APC (10, 11). Dynemine-dependent movement of checkpoint proteins, including Mad2, from the kinetochores along microtubules to the centrosomes occurs at the time of spindle checkpoint silencing in mitosis (12, 13), suggesting that the centrosomes contribute to this process.

The Cdc20 protein contains seven WD motifs that probably fold into a seven-blade β-propeller closed ring structure (14–16) held together by interaction of a β-strand in the first WD motif with the last of three β-strands of the seventh WD motif. When the N-terminal or C-terminal β-strand is deleted, the protein assumes a relaxed open form (17, 18). Whereas all seven of the WD motifs are required for localization of Cdc20 to the kinetochores and to the spindle apparatus (6), it is unclear how these processes occur. Furthermore, it remains to be determined how the structure of Cdc20 relates to its ability to selectively bind substrates or to its subcellular localization, including concentration at the kinetochores.

A meiotic spindle checkpoint apparently functions in mammals during spermatogenesis (19, 20) as it does during oogenesis (21, 22). Disrupting the gene for F box protein β-TrCP1, a ubiquitously expressed substrate-binding subunit of SCF ubiquitin ligase (23) reduced male fertility due to overduplication of centrosomes, formation of multipolar metaphase spindles, misaligned chromosomes, and accumulation of metaphase I spermatocytes (24). These defects were caused in part by the accumulation of Emi1 (25). The meiotic checkpoint appears to be more stringent during spermatogenesis than oogenesis, be-

This paper is available on line at http://www.jbc.org
caused 10–25% of all human fetuses have an abnormal number of chromosomes due mainly (80–90%) to nondisjunction of chromosomes at maternal metaphase I (26).

These studies focused on the role of the last β-stand on the C-terminal WD motif (WD7-β4) in the subcellular localization of Cdc20 during spermatogenesis. They resulted in the identification of speriolin, a spermatogenic cell-specific protein that binds to the WD7-β4 domain of Cdc20, suggesting that it regulates Cdc20 during meiosis in male germ cells.

**EXPERIMENTAL PROCEDURES**

**Yeast Two-hybrid Screening**—Yeast two-hybrid screening was performed on ~3 million clones of a mouse testis cDNA library (Clontech) using pAS2W7D as bait, as described previously (27). Screening, elimination of false positives, and plasmid isolation from three positive (β-galactosidase and His3 gene expression plus 3-aminol-2,4-triazole resistance) clones were performed as recommended by the supplier.

**Construction of cDNA Plasmids**—The cDNA fragments for fusion protein expression were prepared by PCR using Pfu DNA polymerase (Stratagene) or LA-Taq DNA polymerase (Takara) and cloned into the appropriate vectors and then verified by sequencing. For yeast two-hybrid screening, a cDNA encoding the Cdc20 N-terminal segment (amino acids 1–155) and C-terminal segment of the seven WD motif regions (amino acids 442–499) was cloned into the pAS2-1 (Clontech) vector, resulting in pAS2W7D. The cDNA for wild-type or mutant Cdc20 was subcloned into pEYFP-C1 (Clontech) or pFLAG-CMV2 (Sigma) vector to add in-frame N-terminal tags.

To obtain the full-length *Sperm* cDNA, the 5-prime-anchored cDNA ends reaction was performed using mouse testis Marathon-Ready cDNA (Clontech) as template. The cDNA fragments for fusion protein expression were prepared by PCR using *Pfu* DNA polymerase (Stratagene) or LA-Taq DNA polymerase (Takara) and cloned into the appropriate vectors and then verified by sequencing. For yeast two-hybrid screening, a cDNA encoding the Cdc20 N-terminal segment (amino acids 1–155) and C-terminal segment of the seven WD motif regions (amino acids 442–499) was cloned into the pAS2-1 (Clontech) vector, resulting in pAS2W7D. The cDNA for wild-type or mutant Cdc20 was subcloned into pEYFP-C1 (Clontech) or pET-28a(+) (Novagen) vector to add in-frame N-terminal tags.

**PCR-based random mutagenesis** was performed in the presence of 0.5 mM MnCl2, 1 mM dATP, 1 mM dTTP, 0.2 mM dCTP, and 0.2 mM dGTP using Taq DNA polymerase (Invitrogen). To produce mutations in the PCR-amplified fragment, was diluted to 10 times the original volume in PBS containing protease inhibitors (complete EDTA-free protease inhibitor tablet). These studies focused on the role of the last β-stand on the C-terminal WD motif (WD7-β4) in the subcellular localization of Cdc20 during spermatogenesis. They resulted in the identification of speriolin, a spermatogenic cell-specific protein that binds to the WD7-β4 domain of Cdc20, suggesting that it regulates Cdc20 during meiosis in male germ cells.

**Yeast Two-hybrid Screening**—Yeast two-hybrid screening was performed on ~3 million clones of a mouse testis cDNA library (Clontech) using pAS2W7D as bait, as described previously (27). Screening, elimination of false positives, and plasmid isolation from three positive (β-galactosidase and His3 gene expression plus 3-aminol-2,4-triazole resistance) clones were performed as recommended by the supplier.

**Construction of cDNA Plasmids**—The cDNA fragments for fusion protein expression were prepared by PCR using *Pfu* DNA polymerase (Stratagene) or LA-Taq DNA polymerase (Takara) and cloned into the appropriate vectors and then verified by sequencing. For yeast two-hybrid screening, a cDNA encoding the Cdc20 N-terminal segment (amino acids 1–155) and C-terminal segment of the seven WD motif regions (amino acids 442–499) was cloned into the pAS2-1 (Clontech) vector, resulting in pAS2W7D. The cDNA for wild-type or mutant Cdc20 was subcloned into pEYFP-C1 (Clontech) or pFLAG-CMV2 (Sigma) vector to add in-frame N-terminal tags.

To obtain the full-length *Sperm* cDNA, the 5-prime-anchored cDNA ends reaction was performed using mouse testis Marathon-Ready cDNA (Clontech) as template. The cDNA fragments for fusion protein expression were prepared by PCR using *Pfu* DNA polymerase (Stratagene) or LA-Taq DNA polymerase (Takara) and cloned into the appropriate vectors and then verified by sequencing. For yeast two-hybrid screening, a cDNA encoding the Cdc20 N-terminal segment (amino acids 1–155) and C-terminal segment of the seven WD motif regions (amino acids 442–499) was cloned into the pAS2-1 (Clontech) vector, resulting in pAS2W7D. The cDNA for wild-type or mutant Cdc20 was subcloned into pEYFP-C1 (Clontech) or pET-28a(+) (Novagen) vector to add in-frame N-terminal tags.

**PCR-based random mutagenesis** was performed in the presence of 0.5 mM MnCl2, 1 mM dATP, 1 mM dTTP, 0.2 mM dCTP, and 0.2 mM dGTP using Taq DNA polymerase (Invitrogen). To produce mutations in the PCR-amplified fragment, was diluted to 10 times the original volume in PBS containing protease inhibitors (complete EDTA-free protease inhibitor tablet). These studies focused on the role of the last β-stand on the C-terminal WD motif (WD7-β4) in the subcellular localization of Cdc20 during spermatogenesis. They resulted in the identification of speriolin, a spermatogenic cell-specific protein that binds to the WD7-β4 domain of Cdc20, suggesting that it regulates Cdc20 during meiosis in male germ cells.

**Yeast Two-hybrid Screening**—Yeast two-hybrid screening was performed on ~3 million clones of a mouse testis cDNA library (Clontech) using pAS2W7D as bait, as described previously (27). Screening, elimination of false positives, and plasmid isolation from three positive (β-galactosidase and His3 gene expression plus 3-aminol-2,4-triazole resistance) clones were performed as recommended by the supplier.

**Construction of cDNA Plasmids**—The cDNA fragments for fusion protein expression were prepared by PCR using *Pfu* DNA polymerase (Stratagene) or LA-Taq DNA polymerase (Takara) and cloned into the appropriate vectors and then verified by sequencing. For yeast two-hybrid screening, a cDNA encoding the Cdc20 N-terminal segment (amino acids 1–155) and C-terminal segment of the seven WD motif regions (amino acids 442–499) was cloned into the pAS2-1 (Clontech) vector, resulting in pAS2W7D. The cDNA for wild-type or mutant Cdc20 was subcloned into pEYFP-C1 (Clontech) or pFLAG-CMV2 (Sigma) vector to add in-frame N-terminal tags.

To obtain the full-length *Sperm* cDNA, the 5-prime-anchored cDNA ends reaction was performed using mouse testis Marathon-Ready cDNA (Clontech) as template. The cDNA fragments for fusion protein expression were prepared by PCR using *Pfu* DNA polymerase (Stratagene) or LA-Taq DNA polymerase (Takara) and cloned into the appropriate vectors and then verified by sequencing. For yeast two-hybrid screening, a cDNA encoding the Cdc20 N-terminal segment (amino acids 1–155) and C-terminal segment of the seven WD motif regions (amino acids 442–499) was cloned into the pAS2-1 (Clontech) vector, resulting in pAS2W7D. The cDNA for wild-type or mutant Cdc20 was subcloned into pEYFP-C1 (Clontech) or pET-28a(+) (Novagen) vector to add in-frame N-terminal tags.

**PCR-based random mutagenesis** was performed in the presence of 0.5 mM MnCl2, 1 mM dATP, 1 mM dTTP, 0.2 mM dCTP, and 0.2 mM dGTP using Taq DNA polymerase (Invitrogen). To produce mutations in the PCR-amplified fragment, was diluted to 10 times the original volume in PBS containing protease inhibitors (complete EDTA-free protease inhibitor tablet). These studies focused on the role of the last β-stand on the C-terminal WD motif (WD7-β4) in the subcellular localization of Cdc20 during spermatogenesis. They resulted in the identification of speriolin, a spermatogenic cell-specific protein that binds to the WD7-β4 domain of Cdc20, suggesting that it regulates Cdc20 during meiosis in male germ cells.
with 0.5% Triton X-100 for 5 min at 4 °C, and then blocked with 5% normal goat serum in BA-buffer. Cells were labeled for 2 h at room temperature with primary antibodies followed by fluorescein 5-isothiocyanate-conjugated or Alexa-Fluor 546-conjugated secondary antibodies in a humidified chamber. Nuclei were labeled with DAPI, and slides were mounted with Vectashield (Vector). Protein localization was determined at a magnification of 400× using a Zeiss Axioplan fluorescence microscope and a SPOT digital camera (Diagnostic Instruments, Inc.). Final images were prepared using Adobe Photoshop Version 6.

Fractionation of Cell Lysates and Trypsin Protection Assay—Transiently transfected COS-7 cells were lysed and homogenized using a Potter-type homogenizer in Buffer A (50 mM Tris-HCl (pH 8), 0.32 M sucrose, 1 mM EDTA, 1 mM β-mercaptoethanol, complete EDTA-free protease inhibitor tablet (Roche Applied Science)) and then centrifuged at 14,000 × g for 30 min. The resulting supernatant was further centrifuged at 100,000 × g for 1 h to separate the soluble cytosolic fraction (100S) from the insoluble particulate fraction (100P). The 100P pellet was suspended in TN4D containing 1% Nonidet P-40 and 0.5 M NaCl or in PBS containing 1 mM EDTA (PBSE) for Western blotting or trypsin protection assays, respectively. Equal amounts of protein were analyzed by Western blotting.

Four microliters of the 100P pellet obtained from lysates of COS-7 cells expressing EYFP-speriolin were resuspended in PBSE and mixed with 1 µl of 0.25% trypsin-EDTA (Invitrogen) or PBSE and incubated at 37 °C for 5 or 10 min. The reaction was stopped by adding 5 µl of 2× SDS sample buffer. Reaction mixtures were analyzed by Western blotting.

RESULTS

Presence of Cdc20 in Spermatogenic Cells—Northern and Western blotting of gels loaded with equal amounts of materials determined that Cdc20 mRNA (Fig. 1A) and protein (Fig. 1B) are abundant in the adult mouse testis and that Cdc20 protein is detected in the 0.1% Nonidet P-40-insoluble fraction of the tissue examined only in testis. The first wave of spermatogenesis in postnatal mice is relatively synchronous. The insoluble form slightly increased in amount on postnatal day 18, corresponding to the first wave of meiotic divisions, and again on postnatal day 24, when condensing spermatids are first observed (Fig. 1C). Although this suggested that Cdc20 is present in spermatids, it was undetectable in sperm isolated from the cauda epididymis (data not shown). The presence of Cdc20 in spermatogenic cells was confirmed by immunohistochemistry on sections of adult mouse testis. The protein was present at low levels in spermatogonia, detected at higher levels throughout the cytoplasm of midpachytene spermatocytes, and localized at the periphery of the nucleus of late pachytene spermatocytes. The Cdc20 protein was seen throughout the cytoplasm of spermatids during most of the postmeiotic phase of spermatogenesis but not in early elongating spermatids (Fig. 2). The presence of Cdc20 in spermatids was unanticipated, because in somatic cells it peaks in abundance at the G2/M phase and disappears in late mitosis (29).

Molecular Cloning of Speriolin—Because Cdc20-binding proteins regulate its function during mitosis, we hypothesized that novel proteins might be involved in regulating Cdc20 function during meiosis in spermatogenic cells. To identify a Cdc20-binding protein, a mouse testis library was screened using the yeast two-hybrid method. Screening with the full-length Cdc20 protein resulted in a large number of false positives. Therefore, a bait vector (pAS2WD7) was constructed with a cDNA encoding the N-terminal 185 amino acids (containing WD1-β1) and the C-terminal 57 amino acids (containing WD7-β2, -β3, and -β4) of Cdc20 that was expected to express a WD motif with four β strands as a GAL4-BP fusion protein (Cdc20-WD). Empty vector was used as a control. This led to the isolation of three clones, and sequencing determined that their cDNA inserts varied in length but encoded the same protein. A full-length cDNA was assembled from the overlapping sequences of the original clones (nucleotides 109–1607), and a fragment was generated using the 5’-rapid amplification of cDNA ends pro-
Speriolin and Cdc20 during Mouse Spermatogenesis

Speriolin and Cdc20 during Mouse Spermatogenesis

...procedure (nucleotides 1–630). An open reading frame between nucleotides 72 and 1514 encoded a novel protein containing 480 amino acids with a leucine zipper (LZ) motif at the N terminus (amino acids 3–37), a calculated molecular mass of 51,400 daltons, and a predicted pI of 8.16. We named the protein speriolin (SPRN). We confirmed physical interaction between speriolin and Cdc20 by pull-down assays using testis lysates (Fig. 3). We also found that speriolin co-precipitated Cdc27 with speriolin and Cdc20 by pull-down assays using testis lysates (SPRN). We confirmed physical interaction between speriolin and Cdc20 by pull-down assays using testis lysates (SPRN).

Speriolin Expression and Localization—Northern analysis determined that among the mouse tissues examined, the Sprn message is specific to the testis (Fig. 4A). Speriolin protein also was detected only in testis homogenates by Western blotting using either affinity-purified rabbit antisera to His-tagged fusion protein (amino acids 227–480) (Fig. 4B) or to a synthetic peptide (amino acids 309–327) (data not shown). The preimmune serum (data not shown) and the antisera preabsorbed with His-tagged speriolin were negative on testis (Fig. 4B), providing evidence that the antisera are specific to endogenous speriolin. Whereas Cdc20 was found primarily in the 0.1% Nonidet P-40-soluble fraction and in limited amounts in the insoluble fraction of testis homogenates by Western blotting, speriolin was detected only in the insoluble fraction (Fig. 4C). Western blotting of developmental stages of testis further indicated that expression of speriolin begins between days 14 and 16, when pachytene spermatocytes develop, increases by day 22, when postmeiotic spermatids are seen, and is abundant in epididymal sperm but is not detected in adult ovary (Fig. 4D). These observations were consistent with the immunohistochemical analysis. Speriolin is first seen in late pachytene spermatocytes, is abundant throughout spermatocytes undergoing meiotic division, and is present in the cytoplasm of spermatids (Fig. 5).

Immunofluorescence assays on mixed spermatogenic cells isolated from adult mouse testes were used to determine the subcellular distribution of speriolin (Fig. 6). The cytoplasm was weakly stained, but one or two spots in the cytoplasm were more intensely stained in pachytene spermatocytes, spermatocytes undergoing meiotic division, round spermatids, and condensed spermatids, suggesting that speriolin accumulates in the centrosome. This was confirmed by immunostaining of isolated germ cells simultaneously with antibodies to speriolin and to the centrosomal protein pericentrin and determining that the two proteins are co-localized in spermatocytes (Fig. 6). We also confirmed that pericentrin is undetectable in spermiogenesis (30) but found that speriolin was localized to the centrosomes in these cells. These results strongly suggest that speriolin is a spermatogenic cell-specific centrosomal protein.

The Leucine Zipper Motif Is Required for Localization of Speriolin to the Centrosome—A series of EYFP-speriolin dele-
Speriolin mutants were generated to identify the domain responsible for centrosomal targeting. Recombinant EYFP-speriolin expressed in BALB/3T3 cells following transient transfection was localized in one or two spots in the cytoplasm immediately adjacent to the nucleus (Fig. 7A). This localization was comparable with the subcellular distribution of endogenous speriolin in spermatogenic cells (Fig. 6), demonstrating that this heterologous cell system could be utilized for analysis of speriolin localization. Speriolin deletion mutant N76, expressing only the N-terminal 76 amino acids of speriolin containing the LZ domain, was localized adjacent to the nucleus in one or more spots that varied in size between cells, probably due to different levels of expression. This suggests that the N-terminal leucine zipper domain has a key role in targeting speriolin to the centrosome. However, speriolin deletion mutant /H9004, lacking 28 amino acids (residues 426–454) from the C-terminal region that contains two D-box-like domains (RXXL), was distributed in a reticular pattern throughout the cytoplasm. Additional studies will be needed to determine whether this region is involved directly in centrosomal localization or if the pattern seen was caused by a change in speriolin conformation due to the deletion. Speriolin mutant mLZ, in which valines were substituted for Leu-10, Leu-17, and Leu-24 in the LZ domain, was located in multiple perinuclear spots (Fig. 7, A and B). Treating cells with brefeldin A did not alter the distribution of mLZ, indicating that it was unlikely to be accumulating in the Golgi apparatus (data not shown). The result with mutant mLZ provides further evidence that the leucine zipper domain is involved in targeting speriolin to the centrosome.

Full-length speriolin and deletion mutant N76 colocalized with the centrosomal protein pericentrin, confirming their association with the centrosome. An unexpected finding was that pericentrin colocalized in multiple perinuclear spots with spe-
riolin mutant mLZ, suggesting that the association between speriolin and pericentrin is LZ domain-independent. However, the amount of pericentrin appeared to increase in the presence of mLZ (Fig. 7A), suggesting that the speriolin LZ domain is involved in pericentrin turnover. As controls for these experiments, an antibody to α-tubulin was used to verify that the cytoskeleton was not disrupted by the expression of either EYFP alone or the EYFP-tagged mutant speriolin proteins (Fig. 7B). In addition, Western blotting with an antibody to GFP verified that the mutant speriolin proteins were intact (data not shown).

Subcellular Distribution of Speriolin—We examined the distribution of EYFP-speriolin in cell fractions separated by differential centrifugation to determine its association with other cellular components. The low speed supernatant (12,000 × g) of homogenates of COS-7 cells expressing full-length and deletion mutants of EYFP-speriolin were further separated by centrifugation at high speed (100,000 × g) into cytosolic (100S) and microsomal fractions (100P). When equal amounts of protein from each fraction were subjected to SDS-PAGE and Western blotting, EYFP-speriolin was detected mainly in the 100P fraction (Fig. 7C). Because the centrosome is a nonmembranous organelle, we investigated the membrane topology of EYFP-speriolin in the 100P fraction by limited trypsin-digestion analysis. As a control, we monitored endogenous calreticulin, one of the major Ca^{2+}-binding proteins present in the lumen of the endoplasmic reticulum. A level of trypsin digestion that did not affect calreticulin was determined by Western blotting with an antibody to calreticulin. Under the same conditions, EYFP-speriolin and EYFP-speriolin deletion mutant ΔD in the P100 fraction were trypsin-sensitive, consistent with speriolin being at the cytoplasmic face of a nonmembranous component of the particulate fraction, such as the centrosome (Fig. 7D).

The localization of speriolin in the centrosome suggested that it might associate with other centrosomal proteins. We used co-precipitation assays to examine the association between FLAG-speriolin and EYFP-tagged γ-tubulin, ODF1, or ODF2 co-expressed in COS-7 cells. FLAG-speriolin bound to EYFP-tagged γ-tubulin (Fig. 8A), but not to ODF1 or ODF2 (data not shown). The amounts of EYFP-γ-tubulin that co-precipitated with full-length (amino acids 1–480) or the C-terminal half (amino acids 285–480) of speriolin appeared to be less than what co-precipitated with the other speriolin deletion mutants (containing amino acids 70–480 or 161–480). This suggests that the region of speriolin containing amino acids 161–284 participates in the interaction with γ-tubulin and that the LZ domain of speriolin interferes with γ-tubulin association. We also confirmed that γ-tubulin was recovered as a complex with GST-speriolin from testis lysate by pull-down experiments (Fig. 8B). However, it remains to be determined whether the association between γ-tubulin with speriolin is direct or indirect.

The Cdc20-binding Domain on Speriolin—Yeast two-hybrid analysis using Cdc20-WD and N-terminal and C-terminal deletion mutants of speriolin determined that the C-terminal region of speriolin containing amino acids 283–480 is required for Cdc20 binding (Fig. 9A). This region was dissection further using Cdc20 as bait to screen a yeast two-hybrid minilibrary constructed following introduction of random mutations into the cDNA encoding the C-terminal half of speriolin. Fourteen clones were isolated that lacked binding activity, 11 of which had nonsense mutations and three of which had single or double amino acid substitutions. All three substitutions (V305M, K302R/R314Q, and L469P) were located near the ends of the Cdc20-binding region (Fig. 9A, diamonds). This region contained no previously identified protein-protein binding sequences, suggesting that speriolin-Cdc20 binding is dependent on secondary structure or on novel binding sequences.

Further analysis of the physical interaction between speriolin and Cdc20 was carried out using co-immunoprecipitation assays. A series of FLAG-speriolin mutants were co-expressed with EYFP-Cdc20 in COS-7 cells. EYFP-Cdc20 was co-immu-
FIG. 7. Subcellular localization of EYFP-speriolin in BALB/3T3 cells. A, centrosomal localization of EYFP-speriolin in BALB/3T3 cells. Vectors containing full-length Sprn cDNA (wt), the N-terminal 76 amino acids (N76), and a disrupted leucine zipper (mLZ) were transiently transfected into BALB/3T3 cells. Cells were fixed and stained with monoclonal antibody to pericentrin followed by the Alexa 546-labeled anti-mouse IgG and DAPI (blue). The subcellular localization of EYFP (bright yellow-green) and pericentrin (red) were viewed by fluorescence microscopy. Co-localized signals appear in yellow. Empty vector was used as control (EYFP). Bar, 10 μm. B, cDNAs for full-length Sprn (wt) or mutants with a deletion (amino acids 426–454) in the C-terminal region containing the D-box-like sequence (ΔD), containing only the N-terminal 76 amino acids (N76), or with a disrupted leucine zipper (mLZ) were inserted into the mammalian expression vector pEYFP-C1 (EYFP). Transiently transfected BALB/3T3 cells were fixed and stained with monoclonal antibody to α-tubulin followed by the Alexa Fluor 546-labeled anti-mouse IgG and DAPI (blue) for DNA. The subcellular localization of EYFP (bright yellow-green) and α-tubulin (red) were viewed by fluorescence microscopy. C, distribution of EYFP-speriolin in fractions of transiently transfected COS-7 cells. Cells were harvested, disrupted using a Potter-type homogenizer, and then centrifuged at 12,000 × g for 10 min to remove nuclei and mitochondria. The resulting supernatant was further centrifuged at 100,000 × g for 1 h to separate the soluble cytosolic fraction (100S) from the insoluble particulate fraction (100P). Aliquots of fractionated or unfractionated cell extracts (whole) were subjected to 10% SDS-PAGE and analyzed by Western blotting with monoclonal antibodies to GFP, HSP70/HSC70 (a protein loading control), or antiserum to calreticulin (an endoplasmic reticulum-resident protein) as indicated. D, limited trypsin digestion assay on EYFP-speriolin in fractions of transiently transfected COS-7 cells. Aliquots of the isolated particulate fraction (100P) were treated with either 0.05% trypsin or PBS containing 1 mM EDTA for 5 or 10 min followed by 10% SDS-PAGE. Western blotting was performed using antibodies to GFP (upper panel) and calreticulin (lower panel). Untreated 100P fraction was used as a positive control (Input). These results show that speriolin is exposed on the surface of a particulate component.
The Speriolin-binding Domain on Cdc20—The WD7-β4 region is critical for folding of other β-propeller proteins (17, 18) and was included in the Cdc20 bait used to screen the yeast two-hybrid library, leading us to hypothesize that this region of Cdc20 is required for binding to speriolin. This was tested by introducing random mutations into the WD7-β2, -β3, and -β4 domains of Cdc20. When 35 negative clones (no speriolin binding) and 15 positive clones were sequenced, 31 of the negative clones had nonsense mutations between β2 and β3, whereas the other four contained point mutations in WD7-β4 that were predicted to disrupt the β4 structure (E465V, R468Q, E474K, and P477T). In contrast, none of the positive clones that bound to speriolin had mutations that disrupted the β4 structure (R471L). One of the negative clones contained a mutation that altered the length of the β4 structure (E465V), suggesting that this also has a critical role for Cdc20 binding (Fig. 9C).

We used co-immunoprecipitation-Western assays to confirm the association between speriolin and Cdc20. Cell lysates were prepared from COS-7 cells co-expressing FLAG-speriolin and EYFP-tagged mouse Cdc20, p55Cdc (rat ortholog of Cdc20), or Cdc20 with mutations disrupting the WD7-β4 structure (R468Q/W470G or truncated at amino acid 457). Mouse EYFP-Cdc20 and rat EYFP-p55Cdc were co-precipitated with FLAG-speriolin, but EYFP-tagged mutant Cdc20 or EYFP alone were not (Fig. 9D). This was consistent with the yeast two-hybrid results (Fig. 9C) and confirmed that physical interaction occurs between speriolin and Cdc20.

Intracellular Localization of Intact and Mutated Cdc20—Deletion of either the N-terminal or C-terminal β-strands of WD motifs cause other β-propeller proteins to assume a relaxed open form (17, 18). In addition, the WD repeats are required for Cdc20 localization to kinetochores (6). This suggests that Cdc20 is present in the relaxed open form when it accumulates in the cytoplasm of late pachytene spermatocytes. To examine this possibility, EYFP-tagged Cdc20 that either was intact, had point mutations in WD7-β4 (R468Q and W470G), or had WD7-β4 deleted (Δ465–474) was expressed in COS-7 cells. Intact Cdc20 was associated with kinetochores in the nucleus of some cells (Fig. 10A, wt) and distributed in the cytoplasm of others (data not shown), consistent with previous reports of variation in the location of Cdc20 during different stages of the cell cycle (5, 6). In contrast, Cdc20 with the point mutations or with WD7-β4 deleted failed to localize to the nucleus and accumulated in a reticular pattern in the cytoplasm (Fig. 10A). Brefeldin A treatment did not alter the pattern of distribution (data not shown). Controls demonstrated that EYFP alone was located predominantly in the nucleus (data not shown) and confirmed that the mutated proteins were expressed intact (Fig. 10B).

**DISCUSSION**

These studies focused on Cdc20 as an approach to gaining a better understanding of the regulation of meiosis in spermatogenic cells. In the mitotic cell cycle, Cdc20 is present at low levels throughout the nucleus and cytoplasm, is abundant in the centrosomes during interphase, accumulates in the nucleus during prophase, and is concentrated at the kinetochores from late prophase until late anaphase (4–6, 10). During exit from mitosis, Cdc20 is replaced by Cdh1 and is degraded by APC/Cdh1, which remains active throughout the G1 phase (2). We found that Cdc20 accumulates in the cytoplasm of late pachytene spermatocytes during prophase of meiosis I and is present in cells undergoing meiotic division, similar to what occurs during mitosis. This pattern of expression suggests that Cdc20 serves similar purposes during mitosis and meiosis. An unexpected finding in these studies was that Cdc20 is not absent after the meiotic divisions but is present in round spermatids, not seen in early elongating spermatids, and becomes abundant again in late elongating spermatids. However, Cdc20 and the APC are suggested to have other roles in addition to regulation of mitosis (2, 29, 32). Recent studies indicate that the APC/Cdh1 might function outside the cell cycle, both in the degradation of a regulator of transforming growth factor β signaling (29) and in postmitotic neurons (33). This would be consistent with Cdc20 having a novel role during the postmeiotic phase of spermatogenesis in the development or function of spermatids.
Multiple proteins have been identified that are involved in regulating Cdc20 substrate binding and APC activation during mitosis (7–9, 34). In addition, Cdc20/FZY is present in high molecular weight multiprotein complexes both in association with and separate from the APC in HeLa cells (31) and Xenopus egg extracts (9, 35), suggesting that other Cdc20-interacting proteins remain to be identified. We also found that Cdc20 is associated with 0.1% Nonidet P-40-insoluble proteins in testis extracts, whereas it is present in the soluble fraction of tissue culture cells (4). These observations encouraged us to use yeast two-hybrid screening to determine whether meiosis-specific Cdc20-binding proteins are present in spermatogenic cells.

This led to the identification of speriolin, a novel testis-specific protein that co-expresses with Cdc20, localizes to centrosomes in spermatocytes and spermatids, and co-localizes with pericentrin in pachytene spermatocytes. In addition, FLAG-speriolin co-precipitates from COS-7 lysates with γ-tubulin, and EYFP-tagged speriolin co-localizes with pericentrin when transfected into BALB/3T3 cells. Mutational analysis showed that the C-terminal region of speriolin is required for Cdc20 binding and that the N-terminal LZ domain is required for speriolin to accumulate in centrosomes, but not for pericentrin to co-localize with speriolin or for γ-tubulin to co-precipitate with speriolin. The ability of speriolin to bind to Cdc20, localize in centrosomes with pericentrin, and associate with γ-tubulin strongly suggests that it has a meiosis-specific role in centrosomes. However, it remains to be determined whether speriolin associates directly or indirectly with pericentrin and γ-tubulin in centrosomes.

We have confirmed that speriolin binds to testicular Cdc20 by pull-down assay. In addition, Cdc27 was recovered together with Cdc20 from testis lysate, suggesting that speriolin is in a complex with APC<sup>Cdc20</sup>. From co-immunoprecipitation experiments, it is estimated that 10% of Cdc20 is co-precipitated with speriolin.
Mad2 (10) or APC (36) from mitotic HeLa cells or mitotic Xenopus egg extract, respectively. On the other hand, from our pull-down experiments, we estimate that 0.1% of testicular Cdc20 is recovered by GST-speriolin, as judged by Western blotting. However, the physical interaction between speriolin and Cdc20 during spermatogenesis is stage-specific and might occur in a Cdc20 structure-related manner. If speriolin selectively interacts with Cdc20 only when Cdc20 forms a β-propeller structure, the recovery of Cdc20 from testis lysates would be expected to be lower than that from synchronized mitotic cell extracts. It should be noted that speriolin is apparently present in an insoluble complex with APC/Cdc20 in spermatogenic cells because speriolin and Cdc20 were detected in the 0.1% Nonidet P-40-insoluble fraction only in testis for the tissues examined.

Proteins that contain seven WD motifs are able to fold into a seven-blade β-propeller structure by interaction of the first β strand of the N-terminal WD motif (WD1-β1) and the last β strand of the C-terminal WD motif (WD7-β4), and they assume an open relaxed form if either of these β strands is deleted (17, 18). It was shown recently that Cdc20 requires the Mad2/APC-interacting domain (amino acids 1–167) for localization to centrosomes and the N-terminal WD motif for localization to both centrosomes and kinetochores (6). We found that when glutamine and glycine were substituted for Arg-468 and Trp-470 in WD7-β4, Cdc20 was unable to bind speriolin or to enter the nucleus. These mutations also caused Cdc20 to form aggregates in the cytoplasm, similar to what was reported with disruption of folding of another seven-WD motif protein, the G protein β subunit (38). These results strongly suggest that Cdc20 needs to fold into a β-propeller structure to bind speriolin and to enter the nucleus and become available for association with kinetochores.

A hallmark of spermatogenesis is the expression of a substantial number of spermatogenic cell-specific genes that are either novel or orthologues of genes expression in somatic cells and have roles unique to spermatogenic cells (39, 40). In particular, there are meiosis-related proteins such as cyclin A1 (41), Rec8 (42, 43), and STAG3 (44) that supplant or complement similar proteins that function in mitosis. Whereas speriolin lacks homology with known Cdc20-binding or mitosis regulatory proteins that would provide clues about its function in meiosis, the results of these studies suggest some interesting possibilities for examination in future studies. One role of speriolin might be to regulate or stabilize the folding of Cdc20 by binding to WD7-β4. EYFP-Cdc20 failed to localize to the nucleus or to bind speriolin when this domain was deleted or its structure was disrupted by point mutations. Differences in the nuclear envelopes of spermatogenic and somatic cells might require the presence of speriolin for nuclear entry. These differences include the presence of spermatogenic cell-specific nuclear laminas (45–49) and the attachment of the synaptonemal complexes at both ends to the thick nuclear lamina lining the nuclear envelope of spermatocytes (50, 51). The present studies noted an increase in lamin B in the testis at day 18, coincident with the beginning of speriolin synthesis. In addition, the presence of Cdc20 during the postmeiotic phase of spermatogenesis might be attributable to it being bound by speriolin, thereby preventing it from being targeted to the APC. Gene targeting currently is being used to disrupt function of speriolin as an approach to determining its roles in vivo and following meiosis in spermatogenic cells.

Acknowledgments—We are grateful to Dr. Deborah O’Brien for helpful discussions, to Dr. Kiyoshi Miki and Dr. Bonnie Deroo for constructive comments on the manuscript, and to the other members of our laboratory for helpful discussions throughout the course of this work.

REFERENCES
1. Nigg, E. A. (2001) Nat. Rev. Mol. Cell. Biol. 2, 21–32
2. Peters, J. M. (2002) Mol. Biol. Cell 13, 831–843
3. Page, A. M., and Hieter, P. (1999) Annu. Rev. Biochem. 68, 583–609
4. Weinstein, J. (1997) J. Biol. Chem. 272, 28501–28511
5. Kalilo, M., Weinstein, J., Duan, J. R., Burke, D. J., and Gorbsky, G. J. (1998) J. Cell Biol. 141, 1393–1406
6. Kalilo, M. J., Beardmore, V. A., Weinstein, J., and Gorbsky, G. J. (2002) J. Cell Biol. 158, 841–847
7. Hwang, L. H., Lau, L. F., Smith, D. L., Mistrot, C. A., Hardwick, K. G., Hwang, E. S., Amon, A., and Murray, A. W. (1998) Science 279, 1041–1044
8. Kim, S. H., Lin, D. P., Matsumoto, S., Kitazono, A., and Matsumoto, T. (1998) Science 279, 1045–1047
9. Reimann, J. D., Freed, E., Hsu, J. Y., Kramer, E. B., Peters, J. M., and Jackson, P. K. (2001) Cell 105, 455–465
10. Fang, G., Yu, H., and Kirschner, M. W. (1998) Genes Dev. 12, 1871–1883
11. Reimann, J. D., Gardiner, B. E., Margottin-Goguet, F., and Jackson, P. K. (2001) Genes Dev. 15, 3278–3285
12. Taylor, S. S., and McKeon, F. (1997) Cell 89, 727–735
13. Howard, B. D., McEwen, B. F., Cannan, J. C., Hoffman, D. B., Farrar, E. M., Rieder, C. L., and Salmon, E. D. (2001) J. Cell Biol. 155, 1159–1172
14. Lambricht, D. G., Sondek, J., Bohn, A., Skiba, N. P., Hamm, H. E., and Sigler, P. B. (1996) Nature 379, 311–319
15. Sondek, J., Bohn, A., Lambricht, D. G., Hamm, H. E., and Sigler, P. B. (1996) Nature 379, 369–374
16. Wall, M. A., Coleman, D. E., Lee, K., Inzaghi-Llubi, J. A., Posner, B. A., Gilman, G. A., and Sprang, S. R. (1995) Cell 83, 1047–1058
17. Baker, S. C., Saunders, N. F., Willis, A. C., Ferguson, S. J., Hadj, J., and Fushan, B. (1997) J. Mol. Biol. 269, 449–455
18. Neer, E. J., and Smith, T. F. (1996) Cell 84, 175–178
19. Eaker, S. Pyle, A., Cobb, J., and Handel, M. A. (2001) J. Cell Sci. 114, 2953–2965
20. Eaker, S., Cobb, J., Pyle, A., and Handel, M. A. (2002) Dev. Biol. 249, 85–95
21. Wassmann, K., Niault, T., and Maro, B. (2003) Curr. Biol. 13, 1586–1588
22. Woods, L. M., Hodges, C. A., Haart, E., Baker, B. M., Liskay, M., and Hunt,
Speriolin and Cdc20 during Mouse Spermatogenesis

P. A. (1999) *J. Cell Biol.* **145**, 1395–1406

23. Wu, G., Xu, G., Schulman, B. A., Jeffrey, P. D., Harper, J. W., and Pavletich, N. P. (2003) *Mol. Cell* **11**, 1445–1456

24. Guardavaccaro, D, Kudo, Y., Boulaire, J., Barchi, M., Busino, L., Donzelli, M., Margottin-Goguet, F., Jackson, P. K., Yamazaki, L., and Pagano, M. (2003) *Dev. Cell* **4**, 799–812

25. Margottin-Goguet, F., Hsu, J. Y., Loktev, A., Hsieh, H. M., Reimann, J. D., Jackson, P. K. (2003) *Dev. Cell* **4**, 813–826

26. Hassold, T., and Hunt, P. (2001) *Nat. Rev. Genet.* **2**, 280–291

27. Miki, K., and Eddy, E. M. (1998) *J. Biol. Chem.* **273**, 34384–34390

28. O’Brien, D. A. (1993) *Methods Toxicol.* **3A**, 246–264

29. Harper, J. W., Burton, J. L., and Solomon, M. J. (2002) *Genes Dev.* **16**, 2179–2206

30. Manandhar, G., Sutovsky, P., Joshi, H. C., Stearns, T., and Schatten, G. (1998) *Dev. Biol.* **203**, 426–434

31. Lin, M., Chang, J. K., Shankar, D., and Sakamoto, K. M. (2003) *Exp. Mol. Pathol.* **74**, 123–128

32. Gieffers, C., Peters, B. H., Kramer, E. R., Dotti, C. G., and Peters, J. M. (1999) *Proc. Natl. Acad. Sci. U. S. A.* **96**, 11317–11322

33. Zhang, Y., and Lees, E. (2001) *Mol. Cell. Biol.* **21**, 5190–5199

34. Kramer, E. R., Gieffers, C., Hengstschlaeger, M., and Peters, J. M. (1998) *Curr. Biol.* **8**, 1207–1210

35. Lorca, T., Castro, A., Martinez, A. M., Vigneron, S., Morin, N., Sigrist, S., Lehner, C., Doree, M., and Labbe, J. C. (1998) *EMBO J.* **17**, 3565–3575

36. Fang, G., Yu, H., and Kirschner, M. W. (1998) *Mol. Cell* **2**, 163–171

37. Vodernaier, H. C. (2001) *Curr. Biol.* **11**, R834–R837

38. Garcia-Higuera, I., Fenoglio, J., Li, Y., Lewis, C., Panchenko, M. P., Reiner, O., Smith, T. F., and Neer, E. J. (1996) *Biochemistry* **35**, 13985–13994

39. Eddy, E. M. (1995) *Reprod. Fertil. Dev.* **7**, 695–704

40. Eddy, E. M., and O’Brien, D. A. (1998) *Curr. Top. Dev. Biol.* **37**, 1–65

41. Liu, D., Matzuk, M. M., Sung, W. K., Guo, Q., Wang, P., and Welmuth, D. J. (1998) *Nat. Genet.* **20**, 377–380

42. Parisi, S., McKay, M. J., Molnar, M., Thompson, M. A., van der Spek, P. J., van Drunen-Schoenmaker, E., Kanaar, R., Lehmann, E., Hoeijmakers, J. H., and Kohli, J. (1999) *Mol. Cell. Biol.* **19**, 3515–3528

43. Watanabe, Y., and Nurse, P. (1999) *Nature* **400**, 461–464

44. Prieto, I., Suja, J. A., Pezzin, N., Kremer, L., Martinez-A, C., Rafas, J. S., and Barbero, J. L. (2001) *Nat. Cell Biol.* **3**, 761–766

45. Alsheimer, M., and Benavente, R. (1996) *Exp. Cell Res.* **228**, 181–188

46. Furukawa, K., and Hotta, Y. (1994) *Exp. Cell Res.* **212**, 426–430

47. Smith, A., and Benavente, R. (1992) *Differentiation* **52**, 55–60

48. Vester, B., Smith, A., Krohn, G., and Benavente, R. (1993) *J. Cell Sci.* **104**, 557–563

49. Epperson, P., and Giminez-Martın, G. (1972) *Chromosoma* **38**, 405–417

50. Liebe, B., Alsheimer, M., Hoog, C., Benavente, R., and Scherthan, H. (2003) *Mol. Biol. Cell* **15**, 827–837